Custom peptide synthesis is essential at every stage of drug discovery, from initial hit identification through to clinical development. The peptide therapeutics market is expected to grow to $83.57 billion in 2030 at a CAGR of 11.2%[reference:92], reflecting the growing importance of peptides as therapeutic modalities.
In the early discovery phase, custom peptides are used for target validation, assay development, and hit identification. High-throughput peptide libraries enable screening of thousands of sequences to identify initial leads. Once hits are identified, systematic analog synthesis supports structure-activity relationship (SAR) studies to optimize potency and selectivity.
As candidates progress toward development, custom synthesis supports optimization of pharmacokinetic properties through modifications such as PEGylation, cyclization, and amino acid substitution. These modifications can enhance stability, improve bioavailability, and reduce immunogenicity. Our medicinal chemistry support includes guidance on which modifications are most likely to improve drug-like properties.
For preclinical development, we provide GMP-grade peptides for toxicology studies and formulation development. Our integrated approach includes DMPK studies, formulation optimization, and stability testing, ensuring a seamless transition from discovery to development. We also provide regulatory support for IND filings, including comprehensive documentation of synthesis, characterization, and stability data.
For clinical development, we scale up production to meet the demands of Phase I-III trials, maintaining rigorous quality control throughout. Our GMP facility is designed for both clinical and commercial supply, with flexible batch sizes and robust documentation. This end-to-end capability ensures that our customers can progress from lead identification through to commercialization with a single, trusted partner.